Mohammad AskarPublic working copy · medical review pending

Paediatric uveitis and masquerades · 219

Childhood uveitis and masquerades: reassess the diagnosis when the course does not fit

A quiet-looking eye can harbour inflammation; a presumed uveitis can also conceal tumour or infection.

Public working copy · medical review pending. Source, translation and medical checks remain open. Read the limitations in the text and references. These educational materials do not replace individual medical assessment. Published: 2026-11-18T19:45:52+01:00. Internal project references lead to this notice. They are not publicly accessible primary sources; the source limitations remain stated in the text.

Examine both anterior and posterior segments, control inflammation with monitored treatment and reconsider infection or malignancy before escalating blindly.

Terminology and draft status

Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.

01Look beyond redness and joint activity

Paediatric uveitis can be chronic, initially silent and visually damaging through inflammation, treatment and amblyopia. Original 10% of uveitis and posterior 40% children versus 20% adults are untraced population figures; “third US cause of preventable blindness” is not established here as a childhood-specific ranking. Examination difficulty, long treatment and family burden matter without using a ranking as evidence. 1

Do not wait for every child to outgrow disease, but do not assume all need systemic therapy. Some respond to topical treatment; persistent, steroid-dependent or sight-threatening disease may need early steroid-sparing treatment. Joint and ocular activity need not track together: an oligoarticular/ANA-positive risk phenotype does not prove a universal inverse relation between current arthritis severity and uveitis. Keep screening independent of joint symptoms. 1 2

Look patiently for anterior-chamber cells and flare and examine the dilated posterior segment when feasible. Flare reflects protein/barrier disturbance and can persist without active cellular inflammation; zero visible cells does not by itself establish medication-free remission or make every flare an indication to escalate. Synechiae, altered pupil, hypopyon or new strabismus can reveal disease; posterior synechiae can limit the fundus view and require a planned alternative examination. 1

02Use anatomy and age to organise alternatives

Classify by the predominant inflammatory site and describe granulomatous signs separately from cause. The original table wrongly treats mixed etiologies as uniformly granulomatous: Behçet is typically nongranulomatous, JIA usually anterior, and posterior vasculitis does not define a granulomatous category. Keep sarcoid, TB, HLA-B27 disease, MS, Lyme, viruses, syphilis, SLE, Toxocara, toxoplasma and VKH in an appropriate clinical differential rather than using table columns as diagnoses. 1

Original age bands 0–2; 2–10 and 10–20 years are overlapping teaching groups, not exclusion limits. Infection and tumour remain possible beyond them. In a child with unexplained intraocular cells or pseudohypopyon, exclude retinoblastoma before intraocular biopsy or diagnostic PPV; the adult lymphoma sampling pathway cannot simply be transferred to children. 1

Use anatomy and age to organise alternatives
SiteOriginal grouped causes, qualifiedPhenotype boundary
AnteriorSarcoid, TB, Behçet; JIA, HLA-B27(spondylitis, Reiter/reactive arthritis, psoriasis)Behçet/JIA usually nongranulomatous, not one granulomatous group
IntermediateOriginal JIA, MS, LymeAssess actual site; JIA usually anterior, original other column unspecified
Posterior with vasculitisViruses, syphilis, Behçet, SLEVasculitis does not define granulomatous phenotype; other original column unspecified
Posterior without vasculitisToxocara, toxoplasma, TB, VKHPatterns vary, no absolute no-vasculitis rule; original other column unspecified
Use anatomy and age to organise alternatives
Original age bandExamples, not exclusion rules
0–2 yearsViruses, Toxocara, toxoplasma, RB masquerade; all require contextual assessment
2–10 yearsToxocara, toxoplasma, JIA, pars planitis, VKH; overlap
10–20 yearsJIA, pars planitis, VKH; other causes remain possible

03Control inflammation and monitor treatment harm

Coordinate paediatric, rheumatology, uveitis and amblyopia care. The 2019 ACR/AF guideline conditionally favours methotrexate for systemic treatment and monoclonal TNF inhibition in selected severe JIA uveitis; many recommendations have low/very-low evidence certainty. This is not an instruction to start every child on the same regimen. Monitor systemic immunomodulators with the relevant team. 1 2

For elective cataract surgery, sustained inflammatory control is desirable; the original at least 3 months, preferably 6 months is a contextual planning interval, not a reason to delay urgent sight-preserving care. Perioperative topical/systemic steroids and tapering are individual, not mandatory identical doses/routes. Systemic steroid growth/bone harms warrant preventive assessment, not automatic calcium/vitamin-D supplementation for everyone; topical steroids can also cause cataract and pressure rise. 1

Original JIA cataract 62%, band keratopathy 25% and glaucoma 15% have untraced cohorts/denominators. Aphakia with contact-lens/spectacle correction versus IOL is a selected surgical decision; neither universal aphakia, heparin coating nor a large optic is proved ideal for all. Assess inflammation, capsule, age and rehabilitation. Glaucoma needs pressure/nerve monitoring; brimonidine has serious young-child CNS/respiratory risks, prostaglandins are not universally prohibited in every quiet eye, and Ahmed is not the best operation for every case. 1

Selected EDTA chelation can address visually significant, painful or view-obscuring band calcium. Prevent amblyopia through refractive correction and timely management of cataract, PCO or IOL deposits. The original early YAG/IOL-polishing recipe with a focus 50 µm anterior is unvalidated and not a universal child protocol; capsule, age, inflammation, ability and lens-damage risk determine laser versus operative treatment. 1

04Reassess the eight-year-old’s working diagnosis

The original unverified 8-year-old boy had reduced vision, anterior cells+3/+4, posterior synechiae, vitritis and bilateral grade+3 disc swelling. Disc oedema is not automatically papilloedema from raised intracranial pressure. Negative ANA, ACE, Bartonella and TB results did not exclude every sarcoid, JIA or infectious possibility. Steroids and methotrexate were started for severe disease; the case is not comparative evidence of the best regimen. 1

After 2 months of limited response, repeat fluorescein angiography showed peripheral white Dalen-Fuchs-like lesions. Vitiligo reported by his mother and poliosis supported a revised VKH working diagnosis; these findings alone are not pathognomonic. The reported switch to cyclosporine, slow steroid taper and 2-year 10/10 vision without inflammation, complications or steroids remain a single unverified outcome, not proof that cyclosporine is universally more specific or superior for VKH. 1

Examine the posterior segment and revisit later systemic signs when the course is atypical. Original half-dose fluorescein or oral imaging after 10–15 minutes are unverified procedural examples, not dosing instructions. Route, weight, image quality and allergy/emergency preparation need a paediatric imaging protocol. 1

05Distinguish malignancy, degeneration and true infection

Atypical or steroid-resistant inflammation, especially at age extremes, warrants reassessment; transient steroid response does not exclude lymphoma. Adult alternatives include vitreoretinal lymphoma, choroidal melanoma and metastasis; childhood alternatives include retinoblastoma and leukaemia. RP oedema can imitate inflammatory change. Chronic endophthalmitis belongs in the differential but is genuine infection/inflammation, not evidence that all masquerades are noninflammatory. 1

Primary vitreoretinal lymphoma(PVRL; original PIOL) often affects older adults with vitreous cells and yellow-white subretinal/sub-RPE infiltrates or leopard spotting; haemorrhage and disc swelling can occur. Original>60 years, female predominance and 98% bilaterality are untraced tendencies, not exclusion criteria. Disease can begin apparently unilateral and later involve the CNS. 1

Plan diagnostic vitreous sampling with the laboratory: cytology for atypical large B cells, flow/immunophenotype including CD20, molecular clonality/MYD88 and selected cytokines complement each other. IL-10/IL-6>1 supports suspicion but is not a stand-alone diagnosis; a negative sample can be false-negative. Rituximab targets CD20 and methotrexate can be ocular or systemic, but no single local anti-CD20 regimen is the universal standard. Coordinate CNS staging and specialist ocular/systemic therapy. 1 3

Distinguish malignancy, degeneration and true infection
ConditionClues/contextComplicationsNext step and boundary
JIA uveitisWhite eye/ANA risk phenotype, no universal inverse joint relationOriginal cataract 62%, band 25%, glaucoma 15%, oedema; untraced denominatorsMonitored steroid-sparing care; IOL selected; flare alone not automatic escalation
VKHBilateral posterior/panuveitis, disc swelling, later poliosis/vitiligo or neurologic signsExudative detachment, cataract, glaucoma, sunset-glowImaging and systemic assessment, individual steroid/immunomodulation; FFA not sole diagnosis
Toxocara/toxoplasmaOften unilateral posterior inflammation/vitritisTractional detachment, macular scar, cataractAssess infection-specific diagnosis and treatment
PIOL/PVRLOriginal>60 years/98% bilateral unverified; infiltrates/vitritis, response can be transientCNS involvementLaboratory-planned sampling; IL-10/IL-6>1 supportive, not definitive; ocular/systemic therapy
RetinoblastomaOriginal<2 years is not exclusion age; pseudohypopyon/vitreous cells/anterior mimicLife and eye threat (original cell blank)Urgent expert fundus/EUA; exclude before biopsy/PPV
What are the main learning points?

Examine both anterior and posterior segments, control inflammation with monitored treatment and reconsider infection or malignancy before escalating blindly.

When is assessment urgent?

New visual loss, abnormal pupil, hypopyon, leukocoria, severe pain or atypical treatment response needs prompt specialist assessment.

References and access status

  1. 1
    Immutable original export; paediatric uveitis and adult/child masquerade export

    Complete export read; original attribution and any recording/transcript or appointment not independently verified.

  2. 2
    ACR/AF2019 JIA-associated uveitis guideline, selected table 3 and recommendations

    Selected table 3/recommendations and evidence-quality passages read 17November 2026, not every evidence appendix.

  3. 3
    Consensus recommendations for VRL diagnosis; PMID34009095

    Indexed diagnostic biomarker summary inspected 17November 2026; direct PubMed page lacked full abstract. No full-text appraisal.

Original lecture link